Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

Active:	No
Cancer Type:	Kidney Cancer Unknown Primary	NCT ID:	NCT04203901
Trial Phases:	Phase II	Protocol IDs:	CMN-001-1 (primary) NCI-2020-07747
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	CoImmune
NCI Full Details:	http://clinicaltrials.gov/show/NCT04203901

Summary

CMN-001 is an autologous, tumor antigen-loaded dendritic cell immunotherapy. The active
components of CMN-001 are autologous, matured dendritic cells, which have been
co-electroporated with both in vitro transcribed (IVT) RNA from an autologous tumor specimen
and CD40L RNA. CMN-001 is indicated for treatment of intermediate/poor risk patients with
advanced renal cell carcinoma (RCC) in combination with nivolumab plus ipilimumab as first
line therapy and in combination with lenvatinib plus everolimus as 2nd line therapy post 1st
line failure.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.